In the rapidly evolving landscape of metabolic research, the emergence of peptide Mazdutide (also identified as IBI362 or LY3305677) has captured significant attention. As someone deeply interested in the latest advancements in synthetic biology and peptide research, I have followed the deve 11 Feb 2026—Mazdutide, also known as IBI362, isan investigational peptide drugdeveloped by Innovent Biologics for the treatment of obesity and metabolic lopment of this compound closely. It represents a sophisticated approach to modulating metabolic pathways through dual-receptor activation.
Understanding the Mechanism: A Dual-Action Peptide
At its core, Mazdutide is a long-acting, once-weekly, injectable medicine that functions as an analogue of oxyntomodulin (OXM), a natural peptide hormone found in humans. Unlike traditional monotherapies, it is a dual agonist of the GLP-1 receptor (GLP-1R) and the glucagon receptor (GCGR).
Research suggests that Mazdutide was designed to balance the activation of GLP-1 receptor and glucagon receptor to optimize metabolic outcomes. By targeting both receptors simultaneously, this peptide aims to provide results that go beyond what is typically achieved by targeting the GLP-1 receptor alone. Many studies indicate that Mazdutide is a long-acting dual agonist of the glucagon-like peptide-1 receptor and the GCGR, with sp Mazdutide TFA (IBI-362 TFA) | GLP-1R/GCGR Agonist ecific binding affinities (Ki values) that underscore its precision in preclinical models.
Key Research Findings and Observations
In various scientific studies, Mazdutide exhibi 11 Feb 2026—Mazdutide, also known as IBI362, isan investigational peptide drugdeveloped by Innovent Biologics for the treatment of obesity and metabolic ted robust metabolic efficacy across different test groups. For those observing the data, it is clear that mazdutide improves hepatic metabolic function, which is often a f Mazdutide (IBI-362) | GLP-1R/GCGR Agonist ocal point in metabolic research. Furthermore, reports highlight that mazdutide has strong weight-loss efficacy in clinical settings, with some trials demonstrating significant reductions in BMI and waist circumference.
From a research perspective, Mazdutide is the world's first dual GCG/GLP-1 receptor agonist to reach such advanced stages of investigation. Observations have shown excellent weight loss and glucose-lowering effects in subjects, positioning it as a cutting-edge pharmaceutical compound in the field of metabolic science.
Why Mazdutide Stands Out
When comparing this peptida to other options, the dual-agonist approach is frequently cited as a major differentiator. The investigational peptide drug utilizes a fatty acid side chain to prolong its action, making it a synthetic, long-acting peptide suitable for once-weekly administration.
My analysis of the available literature reveals several consistent themes:
* Safety Profile: Mazdutide has a safety and effectiveness profile similar to GLP-1 receptor agonist treatments, which is a critical benchmark in pharmacological development.
* Broad Impact: Beyond weight management, Mazdutide was e oleh W Dong·2025·Dirujuk 14 kali—Mazdutide, a dual agonist of the glucagon-likepeptide-1 receptor (GLP-1R) and the glucagon receptor (GCGR), has been shown to simultaneously reduce body ffective for weight loss in diabetic and non-diabetic patients, suggesting a versatile application in research.
* Systemic Benefits: Recent studies suggest that, it may also contribute to improvements in broader metabolic markers, and in some contexts, exerts multifactorial improvements in cognitive function.
Structural and Scientific Context
As a protein type peptide, the molecular engineering behind this compo Mazdutide (also known as IBI362 or LY3305677)is a dual agonist of the GLP-1 receptor and glucagon receptor. It is an analog of oxyntomodulin (OXM). und is fascinating. Being an analogue of oxyntomodulin (OXM), a natural peptide hormone, it mimics the body's internal signaling systems while providing the stability required for a long-acting therapeutic agent. Whether discussing maz or the full compound dutide, the consensus in research circles is that this molecule represents a significant leap forward in understanding how dual-receptor modulation can influence the human metabolic system.
As we continue to monitor the progress of Mazdutide, it remains a prime example of how targeted peptide synthesis can address complex biological challenges. The combination of its unique dual-agonist mechanism and its favorable pharmacological profile makes it a subject of enduring interest for those of us following the f Mazdutide: An emerging glucagon/GCG-like peptide-1 dual rontiers of metabolic science.